A PYMNTS Company

E.U.: Commission approves acquisition of pharma company by rival Watson

By  |  October 5, 2012

The European Commission has cleared under the EU Merger Regulation the proposed acquisition of the Swiss-based pharmaceutical company Actavis by the generic pharmaceutical company Watson of the U.S. After examining the effects of the proposed transaction on the drug market for anti-depressants and anti-hypertensives, the Commission concluded that the transaction would not significantly effect competition in the European Economic Area

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: EU

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.